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Background and aims: HIV‐1 RNA viral load (VL) in plasma samples of HIV‐1–positive
patients is used to assess the level of viral replication, the risk of disease progression, and the
response and efficacy to antiretroviral treatment. Knowing the performance of different tests
for HIV‐1 RNA detection is, therefore, important for clinical care. This study compared the perfor-
mance of the recently introduced Aptima HIV‐1 Quant Dx assay (Hologic, Inc) and the standard
COBAS AmpliPrep/COBAS TaqMan HIV‐1 v2.0 Test (CAP/CTM2) (Roche Molecular System,
Inc) for HIV‐1 RNA quantitation.
Methods: Assay performance was assessed using 335 clinical samples, a standard HIV‐1 low
VL panel, and 2 diluted samples from well‐characterized patients infected with different HIV‐1
subtypes tested in 5 replicates over 3 days. All samples were tested on both assays to evaluate
inter‐assay agreement, both qualitatively and quantitively. Altogether, we evaluated assay sensi-
tivity, linearity, accuracy, precision, repeatability, and reproducibility.
Results: Assay agreement for qualitative results in 335 clinical samples was fair (80.6%). Cor-
relation of quantitative assay results (n = 164) was excellent (R2 = 0.97), with 96.3% of the results
within the 95% limit of assay agreement (−0.42 to +0.86 log), and 98.8% within 1 log of each
other. Aptima‐HIV‐1 yielded results, on average, 0.22 log higher than CAP/CTM2. Both assays
accurately quantitated the HIV‐1 standard at low VL (R2 ≥ 0.94), with all samples within 0.5 log
of the target.
Conclusion: Aptima‐HIV‐1 assay demonstrated sensitivity, accuracy, reproducibility, and pre-
cision for the detection and quantitation of HIV‐1 RNA across a wide dynamic range of VLs. Its
performance, together with full automation and high throughput, suggests that Aptima‐HIV‐1
could be a suitable assay for reliable monitoring of HIV‐1 VL in patients undergoing treatment.
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The introduction of new antiretroviral agents in the last decade has
significantly improved the efficacy and safety of antiretroviral therapy
(ART) in HIV‐1–infected patients.1 Besides clinical and immunological
monitoring, which are used as complementary evaluations, HIV‐1
RNA quantitation in patients' plasma samples is currently considered
the main approach to monitor ART compliance and success.2-4
Optimal control of HIV‐1 infection is reached when the complete
viral suppression achieved persists over time. Even if full viral suppres-
sion is achievable in most patients (both treatment‐naïve and experi-
enced), some show a transient, low viremia (“blips”).5,6 Some blips
might be considered artifactual variations in viral load (VL) because of
assay variability and laboratory processing inconsistencies,7 not associ-
ated with an increased risk of treatment failure or drug resistance. Key
treatment decisions made at VLs ranging from 1.7 to 3 log copies/mL
need accurate monitoring in clinical samples and, consequently, require
a highly sensitive, precise, and reproducible HIV‐1 RNA quantitation
assay. Other important attributes of a VL assay include the ability to
quantitate HIV‐1 RNA precisely over a wide range of VLs and an
equally good performance on all HIV‐1 subtypes. As assay agreement
on quantitative values is generally good at high VLs but tends to
decrease substantially at low VLs,8-11 the performance characteristics
of an assay able to detect low VLs should be taken into account when
making clinical decisions.
This study compared the performance characteristics of the
recently introduced CE‐(2015) Aptima HIV‐1 Quant Dx assay12 and
the routinely used Roche COBAS AmpliPrep/COBAS TaqMan HIV‐1
v2.0 Test (CAP/CTM2).132 | MATERIALS AND METHODS
2.1 | Clinical samples
The study included clinical samples obtained from HIV‐1–infected
patients attending the Infectious Diseases Unit, St. Orsola Hospital,
Bologna, Italy, for routine monitoring of HIV‐1 VL (January 2014‐
May 2017). The study was approved by the local ethics committee
(737/2016), and the patients provided written informed consent.2.1.1 | HIV‐1 samples
The 335 plasma samples collected in EDTA tubes were tested side‐by‐
side in the Aptima‐HIV‐1 and CAP/CTM2 assays, without further
criteria for selection other than available sample volume.
Tubes were centrifuged for 10 minutes at 1000 to 3000 g for
plasma preparation. All samples were first tested with the CAP/
CTM2 assay.
If the residual plasma volume was ≥1.2 mL, the same samples
were immediately tested in primary tubes on the Hologic Panther
instrument. For samples with less than 1.2 mL residual plasma volume,
0.70 mL plasma was transferred to Hologic specimen aliquot tubes.
Among the samples evaluated in the study, 248 specimens were
derived from HIV‐1 patients infected with B HIV‐1 strains and 87 sam-
ples from other subtypes (A, C, F, G, and CRFs), characterized byphylogenetic analysis of HIV‐1 pol gene (RT and PR).14,15 In particular,
12 samples belonged to subtypes A, 9 to subtypes C, 23 to subtypes F,
14 to subtypes G, and 29 were circular recombinant forms (CRFs).2.2 | HIV‐1 VL assays
Samples in the 2‐assay platforms were processed and tested by trained
operators, by Aptima HIV‐1 Quant Dx assay (cat. no. PRD‐03000) and
Roche CAP/CTM2 (cat. no. 05212294190) according to the assay
manufacturers' package inserts.2.3 | Aptima‐HIV‐1 assay
All the samples were tested in specimen aliquot tubes. Samples were
loaded onto the Panther system (Hologic, Inc). HIV‐1 genomic RNA
was first released using target capture technology and then bound to
magnetic particles. The Aptima HIV‐1 Quant assay uses the TMA
method to amplify 2 regions of HIV‐1 RNA (pol and LTR) from the sam-
ple and amplifies and detects the amplified targets, all in an
automated manner.
The assay's reported lower limit of quantification (LLOQ) is 1.47
log copies/mL, and its upper limit of quantitation is 7 log copies/mL
(Hologic Inc, PI). The reported limit of detection (LoD) of the Aptima‐
HIV‐1 assay is 12 cp/mL. Panther system allows random access testing
of various analytes, processing up to 275 samples in an 8‐hour shift.
The system provides results from 120 samples in about 2.5 hours.2.4 | CAP/CTM2 assay
All the samples were tested in Roche S‐tubes. The sample volume used
was 1 mL. Tubes were loaded onto the Cobas Ampliprep instrument,
which extracts HIV‐1 LTR and gag targets from the sample. Tubes
were then transferred to the COBAS Taqman Analyzer (Roche Molec-
ular Systems, Inc, cat. no. 03121453001), which amplifies and detects
the target sequence in an automated fashion. The reported assay's
LLOQ is 1.39 log copies/mL, and its upper limit of quantitation is 7
log copies/mL (Roche Inc. PI). The reported LoD of this assay is
20 cp/mL. The CAP/CTM platform has an initial capacity for 72 sam-
ples with continuous feeding, which allows 168 samples (1 mL/sample)
to be processed per 8‐hour shift. This system returns results in
4.5 hours.2.5 | Assay assessment using an external quality
panel by Aptima‐HIV‐1 assay
The Acrometrix HIV‐1 linearity panel (ThermoFisher Scientific, Benicia,
California, cat. no. 950470) was used to evaluate both the assays' lin-
earity and accuracy of results at low VLs. The 5 panel members at nom-
inal concentrations of 0, 1.22, 1.52, 1.82, 2.22, and 2.52 log copies/mL
were tested in replicates of 5 in each assay.2.6 | Assay evaluation in 2 clinical samples (subtypes
B and F) by CAP/CTM2 assay and Aptima‐HIV‐1 assay
2 samples with different subtypes (subtype B, subtype F) obtained
from HIV‐1 patients previously well characterized14,15 were serially
LONGO ET AL. 3 of 7&C?JRFѥ1AGCLACѥ0CNMPRQdiluted to 4 target concentrations (about 2.5 to about 5.5 log copies/
mL). Five replicates of each dilution were tested in the Aptima‐HIV‐1
assay on 3 separate days, after storage at 4°C.FIGURE 1 Correlation of assay results in patients' clinical samples
quantified by both assays. A, Deming regression analysis and
correlation; the dotted line represents identity of assay results. B,
Bland‐Altman analysis of agreement between assay results. Dashed
line represents the bias; dotted line represents the assays' limit of
agreement. HIV subtypes are presented as colored circles
TABLE 2A Analysis of 20 discordant samples quantitated by CAP/2.7 | Data analyses
VL values were expressed as log copies/mL. Agreement of the
assays' qualitative results (ie, defining samples as “negative,”
“detected <LLOQ,” and “quantitated”) was determined using a tab-
ular format. For a very small number of plasma samples with dis-
cordant results between the 2 assays (eg, negative or detected
<LLOQ in one assay and quantitated in the other assay), the
patients' immunological data CD4 count and CD4/CD8 ratio, deter-
mined as previously described,15 were considered.
Clinical samples yielding quantitative values in both assays served
to determine the correlation between the paired assay quantitative
values. All statistical analyses were performed using GraphPad Prism
v.6 (GraphPad Software, Inc, San Diego, California). The correlation
was determined by Deming regression analysis with generation of
Pearson's correlation coefficient (R2), as well as Bland‐Altman analysis
and calculation of the average difference between assay results (ie,
bias), the limit of agreement between assay results, and the proportion
of samples with paired results within 1 log copies/mL of each other.
Accuracy was evaluated by comparing assay results with target
values. Linearity of the assay was evaluated by linear regression analy-
sis of the assay results versus the target concentrations. Assay preci-
sion was evaluated by calculating the standard deviation (SD) and
coefficient of variation (%CV) over the replicates tested.CTM2, but either “not detected” or “detected <30 copies/mL” by
Aptima‐HIV
HIV‐1 Subtype Aptima‐HIV‐1 CAP‐CTM2
Patient 1 C <30 31
Patient 2 B <30 31
Patient 3 A <30 32
Patient 4 B <30 32
Patient 5 B <30 35
Patient 6 B <30 38
Patient 7 F <30 403 | RESULTS
3.1 | Assay performance comparison in clinical
samples
Assay performance was compared using all 335 clinical samples (248
HIV‐1 type B and 87 HIV‐1 non‐B samples) with VLs identified by
CAP/CTM2, ranging from undetectable (105/335) to detectable
HIV‐1 RNA amounts (up to 7 log copies/mL).TABLE 1 Concordance of assay results in classifying samples as neg-
ative, detected, or quantitated, in clinical samples
CAP/CTM2
Aptima‐HIV
TotalNot Detected
Detected
<30 copies/mL Quantitated
Not detected 31 0 105
Detected
<20 copies/mL
14 0 46
Quantitated 2 18 184
Total 90 81 164 335
The numbers in circles indicate the agreement between the assays' qualita-
tive results.
Patient 8 B <30 42
Patient 9 F <30 44
Patient 10 B <30 45
Patient 11 A <30 47
Patient 12 B <30 42
Patient 13 G <30 41
Patient 14 B <30 47
Patient 15 B <30 84
Patient 16 B <30 102
Patient 17 B <30 103
Patient 18 C <30 113
Patient 19 B TND 255
Patient 20 C TND 53
Highlighted in gray are the CAP/CTM2 results, which are discordant with
the Aptima‐HIV result.
Abbreviation: TND, target not detected.
TABLE 2B For patients 15‐20, the discrepancy was further analyzed by providing patients' longitudinal clinical and VL data
Patient No. Dates of VL Measurements (Month, Day, Year)
Patient 15 12.05.2014 09.09.2015 02.02.2016 11.05.2016 09.02.2016
CD4 (cells/μL) 772 531 502 630 876
CD4/CD8 ratio 0.97 0.79 0.81 0.97 1.35
CAP/CTM2VL(cp/mL) 6723 25470 23479 84 TND
Patient 16 09.14.2015 07.12.2015 03.30.2016 08.03.2016 01.16.2017
CD4 (cells/μL) 90 131 201 257 305
CD4/CD8 ratio 0.26 0.29 0.23 0.36 0.27
CAP/CTM2VL(cp/mL) 55 64 102 23 <20
Patient 17 10.30.2015 02.16.2016 06.14.2016 08.25.2016 11.02.2016 02.08.2017
CD4 (cells/μL) 10 158 196 193 227 231
CD4/CD8 ratio 0.14 0.18 0.12 0.16 0.24 0.16
CAP/CTM2VL(cp/mL) <20 <20 103 <20 <20 <20
Patient 18 02.20.2015 06.23.2016 10.07.2015 12.19.2016 06.17.2016 08.25.2016 12.13.2016
CD4 (cells/μL) 166 239 258 256 308 263 280
CD4/CD8 ratio 0.25 0.26 0.30 0.22 0.22 0.26 0.30
CAP/CTM2VL(cp/mL) <20 128 168 94 113 <20 TND
Patient 19 10.01.2015 12.09.2015 01.21.2016 05.02.2016 06.22.2016 09.07.2016
CD4 (cells/μL) 20 24 170 176 175 195
CD4/CD8 ratio 0.48 0.53 0.57 0.60 0.65 0.75
CAP/CTM2VL(cp/mL) TND TND TND 255 TND TND
Patient 20 12.14.2015 02.24.2016 04.06.2016 06.15.2016 07.20.2016 08.30.2016
CD4 (cells/μL) 1840 1925 2072 1344 1810 1661
CD4/CD8 ratio 1.6 2.0 1.65 1.66 1.66 1.82
CAP/CTM2VL(cp/mL) TND TND TND 53 TND TND
Highlighted in gray are the CAP/CTM2 results, which are discordant with the Aptima‐HIV result.
Abbreviations: cp/mL, copies/mL; TND, target not detected.
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(undetected, detected <LLOQ, and quantitated) was obtained in
270 out 335 samples (80.6%). Overall, 164 samples showed detect-
able results in both assays. VL was detected <LLOQ by both assays
in 32 samples.
Quantitative results (n = 164) were obtained in both assays with
VLs ranging from 1.4 to 7.0 log copies/mL. Quantitative assay values
were highly correlated (R2: 0.97) (Figure 1A). Assay performance was
checked in plasma samples, with VL detected by both assays, from
HIV‐1 patients infected with either HIV‐1 B strains (114 samples)
or not B HIV‐1 strains (50 samples). Results showed an optimal cor-
relation, regardless of the HIV‐1‐subtype, as demonstrated by
Deming regression analysis (Figure 1A).
Only 2 samples (Figure 1B), with high VL (>5 log copies/mL),
showed VL values differing by >1 log copies/mL between the assays.
On average, Aptima‐HIV‐1 tended to produce VL values 0.22 log
higher than CAP/CTM2 values. However, this trend was not
reflected consistently across the range of VLs, as Aptima‐HIV‐1
values were lower than CAP/CTM2 values for samples with VLs <2
log copies/mL (by 0.05 log) and greater than CAP/CTM2 values for
VLs ≥2 log (Figure 1B). Absolute differences between assay quantita-
tive values were the highest (0.49 log copies/mL) for samples with
high VLs (>5 log copies/mL) and lowest (0.02 to 0.05) for samples
with VLs <4 log copies/mL (data not shown). Overall, 96.3% (158/
164) of the results were within the 95% limit of agreement of theassays (−0.42 to +0.86 log copies/mL) (Figure 1B). Of the 6 outlier
samples (outside the limit of agreement), three differed by <0.5 log
in both assays, one differed by >0.5 log but <1 log, and two by >1
log but <1.5 log.
As shown in Table 1, 65 samples showed different results, more
pronounced when HIV‐1 VL was relatively low. In particular, 31 sam-
ples, undetected by CAP/CTM2, showed a low HIV‐1 RNA amount
(<LLOQ) by Aptima‐HIV‐1, and 14 samples, undetected by Aptima‐
HIV‐1, showed low VL amount (<LLOQ) by CAP/CTM2. In addition,
among the remaining 20 samples with discordant results, 2 samples
quantitated by CAP/CTM2 showed undetectable VL by Aptima‐HIV‐
1, and 18 samples, quantitated by CAP/CTM2, showed HIV‐1 RNA
levels <LLOQ by Aptima‐HIV‐1.
Among these 20 samples with discordant results (Table 2A), 14
showed <30 copies/mL HIV‐1 RNA by Aptima and detectable viral
replication under 50 copies/mL (ranging from 31 to 47 copies/mL) by
CAP/CTM2. The remaining 6 samples (patients 15‐20) presented
<LLOQ levels (sample 15‐18) or undetectable results by Aptima‐HIV‐
1 (patients 19‐20), and VLs ranging from 53 to 255 by CAP/CTM2.
Particular attention was given to these last 6 samples (Table 2AB),
for which corresponding immunological data (CD4, CD8, and CD4/
CD8 ratio) was obtained during follow‐up. For patients 17, 18, and
19, the CAP/CTM2 results might be interpreted as a viral blip, even
if not justified by the CD4 cell count that seem to be stable over time.
Moreover, blood samples from patients 15, 16, and 20 exhibited a
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determined by CAP/CTM2 VL results, accompanied, in further
samples, by a clear improvement in immunological parameters.3.1.1 | HIV‐1 subtypes
Results obtained by the analysis of 87 samples from HIV‐1 patients
infected with subtypes A, C, F, G, and CRFs showed that similar find-
ings could be obtained from samples derived from HIV‐1–infected
subjects with subtypes A and C, irrespective of HIV‐1 RNA amounts,
with no significant difference between the assays used. On the other
hand, Aptima HIV‐1 Quant DX assay was able to detect higher level
of viral replication in samples containing HIV‐1 subtype F, G, and
CRFs, revealing important differences (≥0.5 log) in 13 samples (5
belonging to subtype F, 3 to subtype G, 5 to CRFs), as shown in
Table 3.FIGURE 2 Assay results with the Acrometrix HIV‐1 panel. The mean
values of 5 replicates are plotted with the error bars representing the
SD. The dotted line represents identity of assay values with target
values3.2 | Assay accuracy with a standard panel
The assays' ability to accurately quantitate HIV‐1 RNA at low VLs
was evaluated using the Acrometrix standard at target concentrations
ranging from 1.2 to 2.8 log copies/mL. Assay results showed a very
good precision, with all assay results differing by <0.5 log copies/
mL from the target values, and excellent linearity (R2 ≥ 0.94)
(Figure 2).3.3 | Repeatability, reproducibility, precision, and
linearity with patient's samples of 2 subtypes
Two well‐characterized14,15 clinical samples (subtype B and F) were
tested by Aptima‐HIV‐1 to determine within‐run repeatability,
between‐run reproducibility, precision, and linearity of the assay.
Within‐run repeatability was substantially good, as reflected by an
SD ≤0.16 for the 5 replicates tested (Table 4). Between‐run repeat-
ability was good, with 23 of the 24 results, obtained on 3 differentTABLE 3 Different levels of viral replication obtained by Aptima HIV‐
1 Quant DX and CAP/CTM2 in 13 samples from HIV‐1 patients
infected with different HIV subtypes (F, G, and CRFs)
Sample No.
HIV‐1
Subtype
CAP/CTM2 Aptima‐HIV‐1
cp/mL
log
cp/mL cp/mL
log
cp/mL
Sample A G 121.866 5,09 897.480 5,95
Sample B F 124.296 5,09 814.929 5,91
Sample C CRF12_BF 72.139 4,86 460.368 5,66
Sample D CRF_AG 226.153 5,35 1.138.495 6,06
Sample E F 151.781 5,18 746.774 5,87
Sample F G 24.052 4,38 111.580 5,05
Sample G CRF_AG 63.500 4,80 291.068 5,46
Sample H F 1.189.204 6,08 5.423.568 6,73
Sample I G 17.537 4,24 78.952 4,90
Sample J CRF01_AG 26 1,41 109 2,04
Sample K CRF01_AG 22.727 4,36 88.747 4,95
Sample L F 6.057 3,78 21.128 4,32
Sample M F 206.830 5,32 697.513 5,84
Abbreviation: cp/mL, copies/mL.days, being within 0.5 log of each other (results for the subtype F
at low VL on day 1 differed by >0.5 but <1 log from results on day
2 or 3). Overall precision of the assay was excellent, with 23/24
%CV <4% and all %CVs being <8%.
Accuracy was also excellent, with 22 of 24 results being within 0.5
log of the target, and 2 results differing by >0.5 but <1 log from the tar-
get. Linearity was excellent, as demonstrated by all correlation coeffi-
cients >0.98 (data not shown).4 | DISCUSSION
As HIV‐1 VL monitoring has become the cornerstone for the manage-
ment of HIV‐1‐positive patients during their lifelong treatment regi-
men(s), the assays used to measure HIV‐1 VL must be highly
sensitive, specific, accurate, and precise. In the present study, the
TMA‐based Aptima‐HIV‐1 assay demonstrated sensitivity, reproduc-
ibility, and precision for the detection and quantitation of HIV‐1‐RNA
across a wide dynamic range of VLs (including very low VLs).
Assay agreement for qualitative results in 335 clinical samples was
fair (80.6%). Quantitative results for Aptima‐HIV‐1 and CAP/CTM
were highly correlated (R2 = 0.97) and only 2 of 164 samples quanti-
tated by both assays had results that differed by >1 log copies/mL
but <1.5 log copies/mL. Although Aptima‐HIV‐1 results were on aver-
age slightly higher than CAP/CTM2 results (by 0.22 log), the difference
between assay results was minimal at low VLs (0.05 at VLs 1‐1.99 log;
0.04 at VLs 2‐2.99 log, and 0.02 at VLs 3‐3.99 log).
Among the 65 discordant results, most samples did not show sub-
stantial variations. Indeed, in 45 samples the differences were very
small (less than 30 or 20 copies/mL by one test and undetectable by
the other test) and may not be considered as real conflicting results.
In fact, optimal viral suppression is generally defined as a VL persis-
tently below the level of detection (HIV RNA <20 to 75 copies/mL,
depending on the assay used).2
TABLE 4 Aptima‐HIV results for 2 clinical samples (4 dilutions) tested in 5 replicates in 3 different days
HIV‐1 Subtype B HIV‐1 Subtype F
Targeta Average Aptimab SD %CV Targeta Average Aptimab SD %CV
Day 1 5.50 5.46 0.12 2.25 5.62 5.63 0.09 1.64
4.50 4.35 0.16 3.74 4.62 4.08 0.14 3.33
3.50 3.29 0.06 1.71 3.62 3.11 0.08 2.42
2.50 2.53 0.10 3.88 2.62 1.85 0.15 7.89
Day 2 5.50 5.38 0.03 0.49 5.62 5.61 0.02 0.40
4.50 4.28 0.02 0.46 4.62 4.51 0.10 2.12
3.50 3.35 0.03 0.81 3.62 3.50 0.07 1.97
2.50 2.53 0.08 3.13 2.62 2.62 0.06 2.27
Day 3 5.50 5.06 0.03 0.55 5.62 5.50 0.04 0.77
4.50 3.97 0.15 3.67 4.62 4.44 0.13 3.02
3.50 3.12 0.16 5.23 3.62 3.37 0.11 3.15
2.50 2.34 0.06 2.61 2.62 2.54 0.07 2.68
All data except %CV are in log copies/mL.
aTarget value determined by historical CAP/CTM2 results.
bAverage of 5 replicates.
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but either undetected or detected <LLOQ in Aptima‐HIV‐1,
deserved further analysis. For 14 of these samples, CAP/CTM2
values were <50 copies/mL, while Aptima‐HIV‐1 results were <30
copies/mL, a difference that could considered not to be clinically
significant since consensus threshold defines viral suppression as
<50 copies/mL.2
Among the 6 blood samples only detectable by CAP‐CTM2
(VL >50 HIV‐1 RNA copies/mL, ranging from 53 to 255 copies/mL),
results obtained during follow‐up showed VL values reported as Tar-
get not detectable or very low (<30 copies/mL). In all of these cases,
CD4 values were stable, suggesting that results had to be globally
evaluated considering both VL and CD4 values. However, when a
detectable VL of 50 to 400 copies/mL is preceded or followed by
an undetectable result, testing the sample again is recommended to
avoid an assay artifact or to establish a true viral rebound.16-18
Moreover, the occurrence of so called viral blips (50‐400/1000
copies/mL) during treatment are important events, which could be
misinterpreted as treatment failure and hence may lead to a change
in medication, since the goal of ART is VL suppression to TND or
<50 copies/mL.
While we cannot rule out the probability that proviral HIV‐1 geno-
mic sequences in the plasma could be responsible for the blips (eg,
originating from latently infected cells in the pellet), the small number
of samples prevents any definitive conclusion.
Our results concur with those of other studies that found the
Aptima‐HIV‐1 assay to have a performance comparable with the
CAP/CTM2 test.19-26 Several data19-22,25 showed a small (<0.23
log) positive bias for Aptima‐HIV‐1 VLs, whereas one study found
a small (0.075) negative bias.23 Yet another study found Aptima‐
HIV‐1 to be more sensitive than CAP/CTM2.27 Aptima‐HIV‐1 has
also been shown to have performance characteristics similar
to19,28,29 or better30 than the RealTime HIV‐1 assay (Abbott
Molecular, Des Plaines, Illinois) and superior to the NucliSens
EasyQ HIV‐1 v.2 assay (BioMérieux, Marcy l'Etoile, France)28 and
the Artus HIV‐1 QS‐RGQ assay (Qiagen GmbH, Hilden,
Germany).19Finally, Aptima's performance was equally good in B and non‐B
subtypes, including CRFs, as documented by other studies.20,21,24,28,29
The Aptima assay demonstrated good performance, sensitivity,
precision, and reliability, in addition to an excellent clinical agreement.
Combined with full automation, high throughput, and superior
workflow,31 Aptima‐HIV‐1 is suitable for VL monitoring of HIV‐1
patients during treatment.ACKNOWLEDGEMENTS
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